A Phase 1, First-in-Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients with Recurring Ovarian Cancer and Other Advanced Solid Tumors
Clinical Trial Grant
Awarded By
Context Therapeutics, Inc.
Start Date
February 11, 2026
End Date
February 15, 2031
Awarded By
Context Therapeutics, Inc.
Start Date
February 11, 2026
End Date
February 15, 2031